Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 5/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.41 |
| ▸ | USP14 | P54578 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6706722 | 0.89 | ALDH1A1 (0.43) | CYP2D6KDM4EALDH1A1HRH3 | |
| SCHEMBL6708212 | 0.86 | L3MBTL1 (0.41) | MAPK1KDM4EALDH1A1MCHR1HRH3 | |
| SCHEMBL6708231 | 0.84 | ACHE (0.44) | CYP2D6KDM4EALDH1A1MCHR1HRH3 | |
| SCHEMBL6704583 | 0.83 | MCHR1 (0.45) | KDM4EALDH1A1MCHR1HRH3 | |
| Hydrochloric Acid SCHEMBL6705586 | 0.82 | MCHR1 (0.44) | KDM4EALDH1A1MCHR1HRH3 | |
| SCHEMBL24732909 | 0.80 | PRMT6 (0.56) | GRIN2BCYP1A2CYP2D6MAPK1KDM4E | |
| SCHEMBL29808844 | 0.80 | PRMT6 (0.56) | GRIN2BCYP1A2CYP2D6MAPK1KDM4E | |
| SCHEMBL6223200 | 0.78 | HRH3 (0.61) | CYP2D6KDM4EALDH1A1HRH3 | |
| SCHEMBL6708203 | 0.78 | ACHE (0.46) | CYP1A2CYP2D6MAPK1KDM4EALDH1A1 | |
| SCHEMBL6708035 | 0.77 | GRIN2B (0.42) | GRIN2BKDM4EALDH1A1MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040242572-A1 | New carboxamide compounds having melanin concentrating hormone antagonistic activity, pharmaceutical preparations comprising these compounds and process for their manufacture | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-12-02 | — | — | US | claimed |
| US-20040242572-A1 | New carboxamide compounds having melanin concentrating hormone antagonistic activity, pharmaceutical preparations comprising these compounds and process for their manufacture | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242572-A1 | New carboxamide compounds having melanin concentrating hormone antagonistic activity, pharmaceutical preparations comprising these compounds and process for their manufacture | MCHR2, MCHR1, NPY1R | GRIN2B 1110/4885CYP1A2 749/4885CYP2D6 1590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.